ProQR (PRQR) AI Stock Analysis

• Market Cap: $175.70M
• Dividend Yield: N/A
• Average Volume (3M): 565.84K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.69
• Revenue Growth: 82.38%
• EPS Growth: 3.63%
• Country: US
• Employees: 166
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 105,212,524
• 10 Day Avg. Volume: 334,415
• 30 Day Avg. Volume: 565,835
• PEG Ratio: N/A
• Price to Book (P/B): 1.94
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.02
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.67
• Price Target Upside: 351.18% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 49 Neutral
• Price Target: $1.50 ▼(-11.76%Downside)

ProQR's overall stock score reflects significant challenges in achieving profitability and positive cash flow, despite strong revenue growth. The technical indicators provide some short-term bullish signals, but the longer-term trends remain bearish. The negative P/E ratio highlights valuation difficulties due to ongoing losses, and the absence of a dividend yield limits attractiveness for income investors.

Positive Factors

Market Potential

PRQR's RNA editing therapy, targeting the bile acid transporter for cholestatic diseases, addresses a multi-billion-dollar market, presenting a substantial long-term opportunity.

Technological Advancements

The next-generation AX-0810 has shown a 5.5-fold increase in potency over earlier NTCP EON iterations, along with improved stability in vitro and no evidence of hepatotoxicity or immunostimulatory effects, which indicates a favorable pharmacokinetic, pharmacodynamic, and safety profile.

Negative Factors

Stock Performance

The continued stock decline following a mid-October spike suggests recent market challenges for PRQR.

ProQR Business Overview & Revenue Model

Company Description

ProQR Therapeutics N.V. is a biotechnology company focused on the development of innovative RNA therapies for the treatment of genetic disorders. Headquartered in the Netherlands, ProQR primarily operates within the pharmaceutical and healthcare sectors. The company's core products are based on its proprietary RNA repair platform, which targets genetic mutations at the molecular level to treat rare diseases, with an emphasis on inherited retinal diseases and other genetic conditions.

How the Company Makes Money

ProQR Therapeutics generates revenue through a combination of strategic collaborations, partnerships, and licensing agreements with other pharmaceutical and biotechnology companies. These agreements often involve upfront payments, milestone payments based on the achievement of certain development or regulatory goals, and royalties on future sales of any successfully developed products. Additionally, ProQR may receive funding from government grants and research institutions to support its innovative RNA-based drug development programs. The company's focus on addressing unmet medical needs in rare genetic disorders positions it to potentially benefit from orphan drug designations, which can provide market exclusivity and other financial incentives.

ProQR Financial Statement Overview

Summary

ProQR exhibits strong revenue growth, indicative of expanding operations. However, persistent net losses and negative cash flows highlight financial instability. The balance sheet reflects a relatively healthy leverage position, but the company's path to profitability and positive cash flow remains uncertain.

Income Statement

ProQR has shown significant revenue growth, increasing from $1.35M in 2021 to $19M in TTM 2025. The gross profit margin is strong, but the company is still operating at a net loss, with net profit margins remaining negative. The EBITDA margin is also negative, indicating challenges in achieving operational profitability.

Balance Sheet

The debt-to-equity ratio is relatively low, suggesting manageable leverage levels. The equity ratio shows a stable capital structure with a moderate proportion of equity funding. However, the company has been operating with negative net income, impacting return on equity negatively.

Cash Flow

ProQR has faced issues with free cash flow, which has remained negative, impacting its liquidity position. The operating cash flow to net income ratio is unfavorable due to consistent net losses. Despite this, financing activities have provided cash inflows, supporting operational needs.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
19.01M	18.91M	6.51M	4.04M	1.35M	0.00
	Gross Profit
18.29M	18.91M	6.38M	1.56M	1.35M	-2.19M
	EBIT
-33.39M	-30.47M	-31.86M	-64.72M	-57.19M	-42.37M
	EBITDA
-27.17M	-24.12M	-24.10M	-56.46M	-54.95M	-136.56M
	Net Income Common Stockholders
-30.18M	-27.76M	-28.12M	-64.89M	-61.68M	-46.61M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
132.41M	149.41M	118.92M	94.78M	187.52M	75.84M
	Total Assets
151.69M	167.96M	137.88M	171.32M	209.58M	98.73M
	Total Debt
16.85M	17.22M	19.73M	21.97M	60.37M	34.28M
	Net Debt
-115.56M	-132.19M	-99.19M	-72.80M	-127.15M	-41.56M
	Total Liabilities
72.75M	79.40M	96.49M	106.21M	96.35M	42.18M
	Stockholders Equity
78.94M	88.56M	41.39M	65.50M	113.83M	57.09M
Cash Flow		Free Cash Flow
-37.97M	-37.81M	20.18M	-69.22M	-26.50M	-47.98M
	Operating Cash Flow
-37.06M	-36.39M	21.55M	-68.51M	-26.01M	-47.06M
	Investing Cash Flow
13.44M	-4.07M	4.28M	-702.00K	-425.00K	-924.00K
	Financing Cash Flow
70.19M	70.28M	-2.27M	-30.89M	136.83M	14.50M

ProQR Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.70
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRQR, the sentiment is Positive. The current price of 1.7 is above the 20-day moving average (MA) of 1.66, above the 50-day MA of 1.49, and below the 200-day MA of 2.30, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 55.72 is Neutral, neither overbought nor oversold. The STOCH value of 58.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRQR.

ProQR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SEER	58 Neutral	$123.62M	―	-24.73%	―	-1.02%	-8.59%
Sector *	53 Neutral	$5.14B	3.23	-45.01%	2.85%	17.55%	-0.69%
RGLS	52 Neutral	$546.26M	―	-53.82%	―	―	44.85%
CGEN	51 Neutral	$135.59M	87.50	-24.22%	―	-23.40%	17.80%
TNXP	50 Neutral	$211.90M	―	-91.44%	―	-2.04%	-478.87%
PRQR	49 Neutral	$175.70M	―	-52.64%	―	82.38%	3.63%
SLN	49 Neutral	$238.99M	―	-99.23%	―	-40.10%	-16.60%